This article is more than 5 years old. Information may no longer be current.
Top updates in bone research from ASBMR
Here’s a look at the most popular bone research reports in Endocrine Today from this month’s American Society for Bone and Mineral Research Annual Meeting in Montreal. Readers were interested in alternative to fracture as an outcome in clinical trials, bisphosphonate holidays, AGEs in type 2 diabetes and more.
BMD trajectory can replace fracture as outcome in osteoporosis clinical trials
Bone mineral density at the femoral neck and total hip is a potential surrogate for fracture risk in clinical trials of osteoporosis drugs, according to findings presented at the American Society for Bone and Mineral Research Annual Meeting.
Bisphosphonate drug ‘holidays’ increase fracture risk in women
Discontinuing the use of bisphosphonates for more than 2 years has been linked to increase risk for hip fracture in women, according to research presented at the ASBMR 2018 annual meeting.
Increased cortical advanced glycation end products contribute to brittle bones in men with type 2 diabetes
Researchers found higher advanced glycation end-product content — associated with decreased bone strength — in the cortical bone of men with vs. without type 2 diabetes, according to data presented at the American Society for Bone and Mineral Research Annual Meeting.
BMD dilutes predictive strength of sarcopenia for fractures
When combined with measurements of bone mineral density at the femoral neck, sarcopenia is not an effective predictor of major osteoporotic fracture risk, according to findings presented at the ASBMR 2018 annual meeting.
Risk for second fracture within 1 year nearly double in men vs. women
Compared with women, men are at greater risk for a subsequent fracture, particularly within the first year and up to the first 3 years, after an initial major osteoporotic fracture, but refracture risk declines over time for both sexes.